Company profile

Rein Therapeutics, Inc. CIK 1420565

Ticker

RNTX (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Austin, TX 78758

Fiscal year end

2025 (FY)

Market Data

$0.75

Change

-$0.03

Change %

-3.57%

Volume

650

RNTX · trading date Oct 13, 2026 · previous close $0.78 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials

Revenue

Net income

-$49.87M

Total assets

$24.16M

Total liabilities

$7.24M

Stockholders' equity

$16.92M

Cash & equivalents

$3.22M

Operating income

-$50.63M

Operating cash flow

-$19.36M

Capital expenditures

—

Fiscal year 2025, via 10-K filed 2026-03-26. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance

Operating margin

—

Net margin

—

Free cash flow

—

Free cash flow margin

—

Liabilities / assets

30.0%

Equity / assets

70.0%

CapEx / revenue

—

Operating cash flow / net income

0.39×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History

Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity

2025 $0 -$49.87M $24.16M $7.24M $16.92M

2024 $0 -$62.88M $62.19M $7.80M $54.39M

2023 $0 -$15.73M $106.01M $7.71M $98.30M

2022 $0 -$27.33M $22.01M $3.38M $18.62M

2021 $0 -$26.16M $48.48M $4.58M $43.90M

Company Details

SIC code

2834

Active filer

Yes

Most recent SEC filing

Form 8-K

2026-09-04

Financials filed via

Form 10-K

filed 2026-03-26

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location

Austin, TX 78758

12407 N. MOPAC EXPY.

Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:56 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Texas — Public Companies